Content area
Full Text
Two elderly patients experienced adverse reactions while receiving brentuximab vedotin; one patient developed chills and fever while the other patient experienced peripheral neuropathy.
A 65-year-old man with a history of CD30-positive anaplastic large cell lymphoma started receiving brentuximab vedotin in June 2011, after a relapse of his disease was diagnosed. During the first cycle of his treatment, he received brentuximab vedotin infusion 1 40mg (1.8 mg/kg); his disease responded well and he received afurther 11 cycles of the drug....